SAT-554 Teprotumumab in Graves' Orbitopathy: Extended Outcome Analyses

Objective A multicenter, double-masked, randomized, placebo-controlled, phase two trial of 88 patients with active, moderate-to-severe Graves’ orbitopathy (GO) has demonstrated a significant and rapid response to teprotumumab, an insulin-like growth factor 1 receptor inhibitory monoclonal antibody,...

Full description

Saved in:
Bibliographic Details
Published in:J Endocr Soc
Main Authors: Kahaly, George, Douglas, Raymond, Holt, Robert, Francis-Sedlak, Megan, Perdok, Renee, Sile, Saba, Smith, Terry
Format: Artigo
Language:Inglês
Published: Endocrine Society 2019
Subjects:
Thyroid
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6552477/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-SAT-554
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items